AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9088819 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 8241697 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (2 mg/kg per day)
Number of subjects: 641
Study 8241697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 641
Study 3797204 — intervention group
Group type: EXPERIMENTAL
Intervention: Vision plus kinaesthesis
Number of subjects: 0
Study 3797204 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual
Number of subjects: 0
Study 3797204 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinaesthesis
Number of subjects: 0
Study 29151280 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 ml of a 1.25 kcal/ml nutrition supplement
Number of subjects: 16
Study 29151280 — intervention group
Group type: COMPARATOR
Intervention: High protein nutrition supplement bar
Number of subjects: 16
Study 26791025 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal and lingual infiltrations with 4% articaine and 1:100,000 adrenaline
Number of subjects: 52
Study 26791025 — intervention group
Group type: COMPARATOR
Intervention: Conventional inferior alveolar nerve block (IANB) with 1.8-ml cartridge of 4% articaine and 1:100,000 epinephrine
Number of subjects: 52
Study 24825167 — intervention group
Group type: EXPERIMENTAL
Intervention: ABC/3TC+ATV
Number of subjects: 296
Study 24825167 — intervention group
Group type: COMPARATOR
Intervention: TDF/FTC+ATV/r
Number of subjects: 296
Study 24030557 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing with 1.0 g of Colgate Regular Flavor followed by applying 0.25 g of Tooth Mousse Plus (Group A)
Number of subjects: 9
Study 24030557 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing with 0.25 g of Clinpro Tooth Crème (Group B)
Number of subjects: 9
Study 24030557 — intervention group
Group type: COMPARATOR
Intervention: Brushing with 1.0 g of Colgate Regular Flavor (Group C)
Number of subjects: 9
Study 20681273 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuezhikang Capsule (XZK) at a dose of 60 mg, twice a day, combined with hypotensive drugs
Number of subjects: 110
Study 20681273 — intervention group
Group type: COMPARATOR
Intervention: Control group (hypotensive drugs only)
Number of subjects: 110
Study 20681273 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuezhikang Capsule (XZK) combined with hypotensive drugs
Number of subjects: 110
Study 18184242 — intervention group
Group type: EXPERIMENTAL
Intervention: Introducer Tool (IT)
Number of subjects: 124
Study 18184242 — intervention group
Group type: COMPARATOR
Intervention: Gum Elastic Bougie (GEB)
Number of subjects: 124
Study 16298239 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin (induced hyperinsulinemia)
Number of subjects: 0
Study 14616791 — intervention group
Group type: EXPERIMENTAL
Intervention: ALM mixed with low dose of BCG
Number of subjects: 0
Study 14616791 — intervention group
Group type: COMPARATOR
Intervention: BCG alone
Number of subjects: 0
Study 14616791 — intervention group
Group type: EXPERIMENTAL
Intervention: History of CL and positive LST
Number of subjects: 0
Study 14616791 — intervention group
Group type: EXPERIMENTAL
Intervention: ALM + BCG
Number of subjects: 0
Study 10810001 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipase inhibitor
Number of subjects: 34
Study 10810001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 9299808 — intervention group
Group type: EXPERIMENTAL
Intervention: Panic Appraisal Inventory (PAI)
Number of subjects: 47
Study 8345434 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized albuterol administered by nebulizer
Number of subjects: 33
Study 8345434 — intervention group
Group type: COMPARATOR
Intervention: Aerosolized albuterol administered by MDI-spacer
Number of subjects: 33
Study 8345434 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate in nebulizer group
Number of subjects: 33
Study 8345434 — intervention group
Group type: COMPARATOR
Intervention: Heart rate in MDI-spacer group
Number of subjects: 33
Study 3734027 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospice care
Number of subjects: 96
Study 3734027 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 96
Study 30114458 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral nutrition intervention
Number of subjects: 136
Study 26755098 — intervention group
Group type: EXPERIMENTAL
Intervention: Timothy grass SLIT tablet (2800 bioequivalent allergen unit)
Number of subjects: 102
Study 26755098 — intervention group
Group type: EXPERIMENTAL
Intervention: Ragweed SLIT tablet (12 Ambrosia artemisiifolia 1-U) and grass SLIT tablet
Number of subjects: 102
Study 26755098 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous intake of grass and ragweed SLIT tablets
Number of subjects: 102
Study 26755098 — intervention group
Group type: EXPERIMENTAL
Intervention: Timothy grass SLIT tablet
Number of subjects: 102
Study 26755098 — intervention group
Group type: EXPERIMENTAL
Intervention: Ragweed SLIT tablet and grass SLIT tablet
Number of subjects: 102
Study 23952552 — intervention group
Group type: EXPERIMENTAL
Intervention: Severely obese group (BMI ≥ 35 kg/m2)
Number of subjects: 1060
Study 23952552 — intervention group
Group type: COMPARATOR
Intervention: Non-severely obese group (BMI < 35 kg/m2)
Number of subjects: 1060
Study 23100508 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate 20 mg three times daily
Number of subjects: 20
Study 23100508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 21095309 — intervention group
Group type: EXPERIMENTAL
Intervention: Glue or patch or buttressing
Number of subjects: 1335
Study 21095309 — intervention group
Group type: COMPARATOR
Intervention: Control (single or continuous running sutures or staples)
Number of subjects: 1335
Study 18839047 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased physical education classes (4 classes, 180 min/week) for girls
Number of subjects: 243
Study 18839047 — intervention group
Group type: COMPARATOR
Intervention: Usual physical activity curriculum (90 min/week) for boys
Number of subjects: 243
Study 16893663 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal ultrasound scan
Number of subjects: 12639
Study 16893663 — intervention group
Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 12639
Study 12865592 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estradiol (2 mg/day) + norethisterone acetate (1 mg/day)
Number of subjects: 42
Study 12865592 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (0.05 mg) + norethisterone acetate (0.25 mg)
Number of subjects: 42
Study 12865592 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg/day)
Number of subjects: 42
Study 12865592 — intervention group
Group type: COMPARATOR
Intervention: Control group (no HRT or other treatments)
Number of subjects: 42
Study 12201921 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (1 microg kg(‐1) IV)
Number of subjects: 60
Study 12201921 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (1 mg kg(‐1), IM)
Number of subjects: 60
Study 12201921 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (1.5 mg kg(‐1))
Number of subjects: 60
Study 10356140 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine
Number of subjects: 57
Study 10356140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 8556566 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (50 micrograms b.i.d.)
Number of subjects: 20
Study 8556566 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol (200 micrograms q.i.d.)
Number of subjects: 20
Study 1958987 — intervention group
Group type: EXPERIMENTAL
Intervention: 111In-labelled M8
Number of subjects: 30
Study 1958987 — intervention group
Group type: EXPERIMENTAL
Intervention: 111In-labelled 77-1
Number of subjects: 30
Study 7040695 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% solution of sodium benzyl penicillin
Number of subjects: 260
Study 7040695 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl (saline)
Number of subjects: 260
Study 3908132 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 60 mg/day for 3 weeks
Number of subjects: 11
Study 3908132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 29027510 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical hydroquinone (HQ) 2% applied once nightly for three months
Number of subjects: 37
Study 29027510 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal tranexamic acid (TA) injections administered monthly for three months
Number of subjects: 37
Study 27209504 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant chemoradiation therapy
Number of subjects: 102
Study 27209504 — intervention group
Group type: COMPARATOR
Intervention: Sequential chemoradiation therapy
Number of subjects: 102
Study 27209504 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment sequences
Number of subjects: 102
Study 25684611 — intervention group
Group type: EXPERIMENTAL
Intervention: Game+Therapy
Number of subjects: 101
Study 25684611 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy Only
Number of subjects: 101
Study 25684611 — intervention group
Group type: COMPARATOR
Intervention: Game Only
Number of subjects: 101
Study 25684611 — intervention group
Group type: COMPARATOR
Intervention: No Game+No Therapy
Number of subjects: 101
Study 23730730 — intervention group
Group type: EXPERIMENTAL
Intervention: Alefacept
Number of subjects: 212
Study 23730730 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study 20092954 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer smoking self-report survey
Number of subjects: 575
Study 20092954 — intervention group
Group type: COMPARATOR
Intervention: Paper smoking self-report survey
Number of subjects: 575
Study 20092954 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer alcohol use self-report survey
Number of subjects: 575
Study 20092954 — intervention group
Group type: COMPARATOR
Intervention: Paper alcohol use self-report survey
Number of subjects: 575
Study 20092954 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (C-C, C-P, P-C, P-P)
Number of subjects: 575
Study 19180887 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid withdrawal group
Number of subjects: 45
Study 19180887 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF withdrawal group
Number of subjects: 45
Study 19180887 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy group
Number of subjects: 45
Study 16376977 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (health care providers delivered sun protection advice and materials)
Number of subjects: 728
Study 16376977 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention)
Number of subjects: 728
Study 16376977 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 728
Study 16376977 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 728
Study 12673809 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation Training (PMRT)
Number of subjects: 59
Study 12673809 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 59
Study 11584877 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive aging stereotypes
Number of subjects: 0
Study 11584877 — intervention group
Group type: COMPARATOR
Intervention: Negative aging stereotypes
Number of subjects: 0
Study 9175047 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 72
Study 9175047 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 72
Study 9175047 — intervention group
Group type: COMPARATOR
Intervention: Captopril and Enalapril
Number of subjects: 72
Study 7903214 — intervention group
Group type: EXPERIMENTAL
Intervention: Tertatolol 5 mg alone
Number of subjects: 2706
Study 7903214 — intervention group
Group type: EXPERIMENTAL
Intervention: Tertatolol 5 mg plus diuretic
Number of subjects: 2706
Study 7903214 — intervention group
Group type: EXPERIMENTAL
Intervention: Tertatolol 5 mg plus diuretic and dihydralazine
Number of subjects: 2706
Study 7903214 — intervention group
Group type: EXPERIMENTAL
Intervention: Tertatolol 5 mg
Number of subjects: 2706
Study 7903214 — intervention group
Group type: EXPERIMENTAL
Intervention: Tertatolol
Number of subjects: 2706
Study 3960619 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey‐predominant, 50% medium chain triglyceride formula with 12.5 mg/L of zinc and 2.1 mg/L of copper
Number of subjects: 10
Study 3960619 — intervention group
Group type: COMPARATOR
Intervention: Whey‐predominant, 50% medium chain triglyceride formula with 12.5 mg/L of zinc and 0.9 mg/L of copper
Number of subjects: 10
Study 3960619 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received 12.5 mg/L of zinc
Number of subjects: 10
Study 30339465 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite Physical Activity Score (combination of reported and accelerometer-derived PA data)
Number of subjects: 3549
Study 30339465 — intervention group
Group type: COMPARATOR
Intervention: Self-report only
Number of subjects: 3549
Study 30339465 — intervention group
Group type: COMPARATOR
Intervention: Accelerometer only
Number of subjects: 3549
Study 30339465 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report plus accelerometer
Number of subjects: 3549
Study 30339465 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation set
Number of subjects: 3549
Study 27403058 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone gas (O3) applied for 12 seconds
Number of subjects: 30
Study 27403058 — intervention group
Group type: COMPARATOR
Intervention: Saline solution used for irrigation
Number of subjects: 30
Study 24691112 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic testing scenario
Number of subjects: 257
Study 24691112 — intervention group
Group type: COMPARATOR
Intervention: Standard blood testing scenario
Number of subjects: 257
Study 24691112 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic testing scenario with higher genetic literacy
Number of subjects: 257
Study 20678906 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg
Number of subjects: 80
Study 20678906 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 21105483 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous morphine (0.35 mg/kg)
Number of subjects: 50
Study 21105483 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine (0.25 mg/kg)
Number of subjects: 50
Study 21105483 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 21105483 — intervention group
Group type: COMPARATOR
Intervention: Group E (Intravenous)
Number of subjects: 50
Study 18681202 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential chemotherapy and radiotherapy
Number of subjects: 63
Study 18681202 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant chemoradiotherapy
Number of subjects: 63
Study 15938592 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-1b (250 microg subcutaneous) with a slow, four-stage, 4-week titration
Number of subjects: 98
Study 15938592 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-1b (250 microg subcutaneous) with a rapid, two-stage, 2-week titration
Number of subjects: 98
Study 15938592 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 12933390 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% plus clonidine 1 micro g/mL
Number of subjects: 34
Study 12933390 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine 0.2%
Number of subjects: 34
Study 10739849 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated maternal total homocysteine concentrations (fasting >18.3 micromol/l and/or 6 h after methionine load >61.5 micromol/l)
Number of subjects: 19
Study 10739849 — intervention group
Group type: EXPERIMENTAL
Intervention: Single chorionic vascular elements in women with elevated total homocysteine concentrations
Number of subjects: 19
Study 10739849 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting total homocysteine
Number of subjects: 19
Study 10739849 — intervention group
Group type: COMPARATOR
Intervention: Normal total homocysteine concentrations
Number of subjects: 19
Study 9014601 — intervention group
Group type: EXPERIMENTAL
Intervention: Epogam evening primrose oil
Number of subjects: 60
Study 9014601 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 60
Study 1574915 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined immunization with purified Vero cell rabies vaccine and Typhim Vi
Number of subjects: 104
Study 1574915 — intervention group
Group type: COMPARATOR
Intervention: Purified Vero cell rabies vaccine
Number of subjects: 104
Study 1574915 — intervention group
Group type: COMPARATOR
Intervention: Typhim Vi
Number of subjects: 104
Study 6397973 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg amphetamine sulfate
Number of subjects: 23
Study 6397973 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg amphetamine sulfate
Number of subjects: 23
Study 6397973 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg ephedrine hydrochloride
Number of subjects: 23
Study 6397973 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg ephedrine hydrochloride
Number of subjects: 23
Study 6397973 — intervention group
Group type: EXPERIMENTAL
Intervention: Active drug (combined results of amphetamines and ephedrine)
Number of subjects: 23
Study 6397973 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 29147810 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate intravaginal ring
Number of subjects: 18
Study 29147810 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 18
Study 28371401 — intervention group
Group type: EXPERIMENTAL
Intervention: AcrySof IQ® SN60WF
Number of subjects: 50
Study 28371401 — intervention group
Group type: COMPARATOR
Intervention: Tecnis® ZCB00
Number of subjects: 50
Study 25415933 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 42
Study 25415933 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 42
Study 25415933 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aerobic and strength training
Number of subjects: 42
Study 25415933 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 42
Study 23137180 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA) with MPA
Number of subjects: 629
Study 23137180 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus (Tac) with MPA
Number of subjects: 629
Study 21652780 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Education and Counseling Intervention
Number of subjects: 389
Study 18797683 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfusion technique
Number of subjects: 39
Study 18797683 — intervention group
Group type: COMPARATOR
Intervention: Balloon technique
Number of subjects: 39
Study 17134627 — intervention group
Group type: EXPERIMENTAL
Intervention: GIK infusion (30% glucose, 50 IU of insulin, 80 mEq of potassium chloride infused at 1.5 ml/kg/hour over 24 hours)
Number of subjects: 73
Study 17134627 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 73
Study 12694779 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IP)
Number of subjects: 45
Study 12694779 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study 10971306 — intervention group
Group type: EXPERIMENTAL
Intervention: S-heparin (50 IU kg(‐1) via i.v.)
Number of subjects: 18
Study 10971306 — intervention group
Group type: EXPERIMENTAL
Intervention: LMW heparin (50 IU kg(‐1) via i.v.)
Number of subjects: 18
Study 10971306 — intervention group
Group type: EXPERIMENTAL
Intervention: S-heparin (via s.c. injection)
Number of subjects: 18
Study 10971306 — intervention group
Group type: EXPERIMENTAL
Intervention: LMW heparin (via s.c. injection)
Number of subjects: 18
Study 10971306 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline via i.v. injection)
Number of subjects: 18
Study 8607575 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE(1)
Number of subjects: 35
Study 8607575 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 35
Study 1451221 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine infusion (0.5‐2.0 micrograms.kg‐1 x min‐1)
Number of subjects: 0
Study 1451221 — intervention group
Group type: EXPERIMENTAL
Intervention: hANP infusion (0.05‐0.2 microgram.kg‐1 x min‐1)
Number of subjects: 0
Study 1451221 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane (increased concentration)
Number of subjects: 0
Study 3967529 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Body Weight (TBW)
Number of subjects: 54
Study 3967529 — intervention group
Group type: EXPERIMENTAL
Intervention: Ideal Body Weight (IBW)
Number of subjects: 54
Study 3967529 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted Body Weight (ABW)
Number of subjects: 54
Study 29452929 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 37
Study 29452929 — intervention group
Group type: EXPERIMENTAL
Intervention: Iontophoresis
Number of subjects: 37
Study 29452929 — intervention group
Group type: COMPARATOR
Intervention: Phonophoresis
Number of subjects: 37
Study 29058358 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (0.5 or 2 mg)
Number of subjects: 42
Study 29058358 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (7.5 mg)
Number of subjects: 42
Study 29058358 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (3 mg)
Number of subjects: 42
Study 29058358 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 27305830 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication continuation (quetiapine 400 mg/day)
Number of subjects: 102
Study 27305830 — intervention group
Group type: COMPARATOR
Intervention: Medication discontinuation (placebo)
Number of subjects: 102
Study 27305830 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 102
Study 25077511 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic surgery
Number of subjects: 160
Study 25077511 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 160
Study 22311903 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of yohimbine (5.4 mg) and atomoxetine (18.0 mg)
Number of subjects: 17